Baxalta (BXLT) stock is rising on Monday after the companies announced this morning that Dublin-based bio-pharmaceutical company Shire will buy Baxalta for $32 billion in cash and stock.

Shire has completed its $32 billion merger with biotech Baxalta in a move aimed at creating a global leader in rare diseases. Baxalta only spun off from Baxter last summer – and Shire moved ...

Mumbai: Takeda Biopharmaceuticals India Pvt Ltd (formerly known as Baxalta Bioscience India Private Limited), part of a ...

With Shire offering to acquire Baxalta for more than $30 billion, we decided to check TheStreet Quant Ratings for stocks in the pharmaceuticals subsector that would be good investments. With Shire ...

Baxalta, which spun off from Baxter last summer but was immediately courted by Shire, made no comment on its website. Related stories: Pfizer to end $160bn merger with Allergan following US tax ...

Takeda-owned Baxalta announced the second-highest number of price increases, with 53 hikes planned so far, followed by Belgian drugmaker UCB Pharma, which intends to raise prices on 40 unique drugs.

Takeda’s (NYSE:TAK) Baxalta unit is planning increases for 53 drugs, while UCB (OTCPK:UCBJF) (OTCPK:UCBJY) is looking at raise prices for 40 unique brands, Reuters said. Sanofi (NASDAQ ...

Annapurna comes with more than 20 years of experience in the pharmaceutical and biotechnology industry across India and ...

Although the 2015 Baxalta spinoff was successful, Baxter’s financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends.

(Funded by Takeda Development Center Americas and Baxalta Innovations; ClinicalTrials.gov number, NCT03393975.) We are conducting a phase 3, multinational, prospective, open-label, randomized ...

GR was a paid consultant to Cubist Pharmaceuticals on a previous project on "Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant pseudomonas aeruginosa ...

Drugmaker Shire is hoping to buy Baxalta, a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases. The London-listed group ...